AU2003208228A1 - Formulations and methods of using nitric oxide mimetics in cancer treatment - Google Patents

Formulations and methods of using nitric oxide mimetics in cancer treatment

Info

Publication number
AU2003208228A1
AU2003208228A1 AU2003208228A AU2003208228A AU2003208228A1 AU 2003208228 A1 AU2003208228 A1 AU 2003208228A1 AU 2003208228 A AU2003208228 A AU 2003208228A AU 2003208228 A AU2003208228 A AU 2003208228A AU 2003208228 A1 AU2003208228 A1 AU 2003208228A1
Authority
AU
Australia
Prior art keywords
formulations
methods
nitric oxide
cancer treatment
oxide mimetics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003208228A
Other languages
English (en)
Inventor
Michael A. Adams
Charles H. Graham
Jeremy P. W. Heaton
Lynne-Marie Postovit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DMK Pharmaceuticals Corp
Original Assignee
Queens University at Kingston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queens University at Kingston filed Critical Queens University at Kingston
Publication of AU2003208228A1 publication Critical patent/AU2003208228A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003208228A 2002-03-06 2003-03-06 Formulations and methods of using nitric oxide mimetics in cancer treatment Abandoned AU2003208228A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36296902P 2002-03-06 2002-03-06
US60/362,969 2002-03-06
US36262002P 2002-03-07 2002-03-07
US60/362,620 2002-03-07
PCT/CA2003/000313 WO2003074082A1 (en) 2002-03-06 2003-03-06 Formulations and methods of using nitric oxide mimetics in cancer treatment

Publications (1)

Publication Number Publication Date
AU2003208228A1 true AU2003208228A1 (en) 2003-09-16

Family

ID=27791719

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003208228A Abandoned AU2003208228A1 (en) 2002-03-06 2003-03-06 Formulations and methods of using nitric oxide mimetics in cancer treatment

Country Status (5)

Country Link
EP (1) EP1492567A1 (enExample)
JP (1) JP2005527510A (enExample)
AU (1) AU2003208228A1 (enExample)
CA (1) CA2478145A1 (enExample)
WO (1) WO2003074082A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
PL2348114T3 (pl) 2004-04-21 2019-08-30 Alexion Pharmaceuticals, Inc. Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość
US7329495B2 (en) 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
WO2005120493A1 (en) * 2004-06-10 2005-12-22 Tohoku University Anticancer effect enhancer
AU2005274546B2 (en) * 2004-08-19 2011-02-03 Switch Biotech, Llc Use of a PDE5 inhibitor for treating and preventing hypopigmentary disorders
EP1759700B1 (en) * 2004-08-19 2009-08-05 Switch Biotech, LLC Use of a PDE5 inhibitor for treating and preventing hypopigmentary disorders
US20070135380A1 (en) 2005-08-12 2007-06-14 Radiorx, Inc. O-nitro compounds, pharmaceutical compositions thereof and uses thereof
AU2012203798B2 (en) * 2005-08-12 2013-11-07 Northrop Grumman Systems Corporation O-nitro compounds, pharmaceutical compositons thereof and uses thereof
CA2710349A1 (en) * 2007-12-27 2009-07-09 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide -donating compounds and uses thereof
JP5467259B2 (ja) * 2008-03-13 2014-04-09 国立大学法人 千葉大学 シスプラチン効果増強剤及び抗癌剤キット
WO2009137071A1 (en) * 2008-05-09 2009-11-12 Duke University Treatment for diseases relying on discovery that thioredoxin mediates nitric oxide release in cells
EP2658979B1 (en) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
WO2012118042A1 (ja) * 2011-02-28 2012-09-07 独立行政法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
JP5842367B2 (ja) * 2011-04-07 2016-01-13 ニプロ株式会社 抗癌剤増感剤
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
EP3129015B1 (en) 2014-04-08 2021-07-14 The Methodist Hospital Inos-inhibitory compositions and their use as breast cancer therapeutics
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
MX389350B (es) 2014-12-05 2025-03-19 Alexion Pharma Inc Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones.
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
KR102644116B1 (ko) 2015-08-17 2024-03-05 알렉시온 파마슈티칼스, 인코포레이티드 알칼린 포스파타제의 제조
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
CA3019726A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
EP3464573A4 (en) 2016-06-06 2020-02-19 Alexion Pharmaceuticals, Inc. EFFECTS OF METALS ON THE PRODUCTION OF ALKALINE PHOSPHATASES
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
JP2020512363A (ja) 2017-03-31 2020-04-23 アレクシオン ファーマシューティカルズ， インコーポレイテッド 成人及び青年における低ホスファターゼ症（ｈｐｐ）を治療する方法
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
JP2023504208A (ja) 2019-12-09 2023-02-01 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼポリペプチド及びその使用方法
US12083169B2 (en) 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
CN114869894A (zh) * 2022-05-10 2022-08-09 福州大学 一种小分子化合物在制备作为尿激酶受体抑制剂药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LV11542B (en) * 1995-03-30 1997-02-20 Latvijas Organiskas Sintezes Instituts Substituted 1,3,9,11-tetraoxa-4,5,7,8-tetraazaundecadien-4,7-dioxides-5,7, preparation and use thereof
WO1999003462A1 (en) * 1997-07-14 1999-01-28 Brigham And Women's Hospital Modification of nitric oxide activity to treat fas-induced pathologies
JP2004508279A (ja) * 2000-01-26 2004-03-18 シーダース　シナイ　メディカル　センター 薬剤を異常脳領域及び／又は悪性腫瘍にデリバリーするためにカリウムチャンネル活性化を用いる方法
US20010038832A1 (en) * 2000-04-11 2001-11-08 Benjamin Bonavida Nitric oxide and analogues thereof effectuate sensitization of neoplasm and immunologically undesired tissues to cytotoxicity
DE60106905T2 (de) * 2000-04-26 2005-12-01 Cellegy Pharmaceuticals, Inc., South San Francisco Formulierungen und verfahren zur verwendung von stickstoffmonoxid mimetika gegen einen malignen zellphänotyp

Also Published As

Publication number Publication date
WO2003074082A1 (en) 2003-09-12
EP1492567A1 (en) 2005-01-05
CA2478145A1 (en) 2003-09-12
JP2005527510A (ja) 2005-09-15

Similar Documents

Publication Publication Date Title
AU2003208228A1 (en) Formulations and methods of using nitric oxide mimetics in cancer treatment
AU2003284242A1 (en) Methods and compositions for use in treating cancer
AU2003293376A1 (en) Anti-angiogenic compounds and their use in cancer treatment
AU2003265225A1 (en) Preparations for topical skin use and treatment
AU2002341566A1 (en) Treatment and prevention of mucositis in cancer patients
AU2001283285A1 (en) Antimicrobial composition and methods of use in the treatment of disease
AU2002952597A0 (en) Topical parasiticide formulations and methods of treatment
AU2003298551A1 (en) Nitric oxide and its biomedical significance
AU2002316201A1 (en) Methods of using colony stimulating factors in the treatment of tissue damage and ischemia
GB0212405D0 (en) Composition and its therapeutic use
AU2003274963A1 (en) Mda-7 and free radicals in the treatment of cancer
SG110107A1 (en) Compound and use in treatment
AU2003248763A1 (en) Methods and contrast agents useful in quantifying nitric oxide
AU2003250831A1 (en) Use of hec1 antagonists in the treatment of proliferative disorders and cancer
AU2003219664A1 (en) Methods and therapeutic compositions in the treatment of advanced cancer
AU2003245858A1 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
AU2003209459A1 (en) Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
AU2003291896A1 (en) Saponins and sapogenins for use in combination therapy for cancer
AU2003240446A1 (en) Use of mob-5 in pain
AU2003244437A1 (en) Quinoxalinones and their use especially in the treatment of cardiovascular diseases
EP1643959A4 (en) MIXTURES OF CALCITONIN MEDICAMENT OLIGOMER CONJUGATES AND METHOD OF USE IN PAIN TREATMENT
AU2003225191A1 (en) Methods useful in treatment and prevention of hiv infection
AU2002345165A1 (en) The use of rhein and derivatives thereof in pain treatment
AU2003227656A1 (en) Methods and compositions for treatment of cancer pain
AU2003246880A1 (en) Alkaloid-derived compounds and use thereof in cancer and malaria treatment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase